What Makes Biogen (BIIB) an Attractive Long-Term Holding?

Core Insights - Patient Opportunity Equity Strategy achieved a return of 5.99% net of fees in Q4 2025, outperforming the S&P 500 Index which returned 2.65% [1] - The overall market had a strong year with a return of 17.9%, marking the seventh-best three-year period in market history [1] - The strategy outperformed the S&P 500 for the third consecutive year with a total return of 26.1% in 2025 [1] Company Insights - Biogen Inc. (NASDAQ:BIIB) specializes in therapies for neurological and neurodegenerative diseases, with a market capitalization of $27.88 billion [2] - As of March 04, 2026, Biogen's stock closed at $189.94 per share, with a one-month return of 2.47% and a 52-week gain of 28.89% [2] - The strategy increased its exposure to Biogen by purchasing long-dated call options expiring in 2028 with a strike price of $150, indicating a long-term positive outlook on the company [3] - Biogen is expected to benefit from late-stage pipeline assets and a growing Alzheimer's franchise, with a focus on blood-based biomarkers and subcutaneous injections [3] - The company aims to position itself across multiple stages of the Alzheimer's disease lifecycle, similar to its historical approach in multiple sclerosis [3]